H. B. Carter and D. S. Coffey, The prostate: an increasing medical problem. The Prostate, pp.39-48, 1990.

K. L. Lee and D. M. Peehl, Molecular and cellular pathogenesis of benign prostatic hyperplasia. The Journal of urology, pp.1784-1791, 2004.

G. Kramer, D. Mitteregger, and M. Marberger, Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology, pp.1202-1216, 2007.

Y. Allory and A. De-la-taille, Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. The Prostate, pp.1774-1780, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00440934

J. M. Schenk, A. R. Kristal, M. L. Neuhouser, C. M. Tangen, E. White et al., Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial, The Prostate, vol.95, issue.4, pp.1303-1311, 2009.
DOI : 10.1002/pros.20974

G. Hubmer, Inflammation of the hypertrophic prostate], Zeitschrift fur Urologie und Nephrologie, vol.61, pp.801-804, 1968.

C. G. Roehrborn, Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia, Reviews in urology, vol.7, issue.8, pp.43-51, 2005.

J. C. Nickel, C. G. Roehrborn, M. P. Leary, D. G. Bostwick, M. C. Somerville et al., The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial, European Urology, vol.54, issue.6, pp.1379-1384, 2008.
DOI : 10.1016/j.eururo.2007.11.026

C. H. Minnery and R. H. Getzenberg, BENIGN PROSTATIC HYPERPLASIA CELL LINE VIABILITY AND MODULATION OF JM-27 BY DOXAZOSIN AND IBUPROFEN, The Journal of Urology, vol.174, issue.1, pp.375-379, 2005.
DOI : 10.1097/01.ju.0000161598.24740.34

S. Falahatkar, G. Mokhtari, F. Pourreza, S. A. Asgari, and A. N. Kamran, Celecoxib for Treatment of Nocturia Caused by Benign Prostatic Hyperplasia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study, Urology, vol.72, issue.4, pp.813-816, 2008.
DOI : 10.1016/j.urology.2008.04.069

J. P. Raynaud, H. Cousse, and P. M. Martin, Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. The Journal of steroid biochemistry and molecular biology, pp.233-239, 2002.

C. W. Bayne, F. Donnelly, M. Ross, and F. Habib, Serenoa repens (Permixon???): A 5?-reductase types I and II inhibitor?new evidence in a coculture model of BPH, The Prostate, vol.21, issue.4, pp.232-241, 1999.
DOI : 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0

D. Nicola, S. Toscano, and V. , Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. The Prostate, pp.77-83, 1998.

D. Silverio, F. Eramo, G. Lubrano, C. Flammia, G. P. Sciarra et al., Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients, European urology, vol.21, issue.15, pp.309-314, 1992.

F. Vacherot, M. Azzouz, S. Gil-diez-de-medina, M. Colombel, A. De-la-taille et al., Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. The Prostate, pp.259-266, 2000.

M. Paubert-braquet, H. Cousse, J. P. Raynaud, J. M. Mencia-huerta, and P. Braquet, Effect of the Lipidosterolic Extract of Serenoa repens (Permixon<sup>&reg;</sup>) and Its Major Components on Basic Fibroblast Growth Factor-Induced Proliferation of Cultures of Human Prostate Biopsies, European Urology, vol.33, issue.3, pp.340-347, 1998.
DOI : 10.1159/000019570

R. Vela-navarrete, M. Escribano-burgos, A. L. Farre, J. Garcia-cardoso, F. Manzarbeitia et al., Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. The Journal of urology, pp.507-510, 2005.

M. Paubert-braquet, J. M. Mencia-huerta, H. Cousse, and P. Braquet, Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon??) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.57, issue.3, pp.299-304, 1997.
DOI : 10.1016/S0952-3278(97)90548-2

G. Bonvissuto, L. Minutoli, G. Morgia, A. Bitto, F. Polito et al., Effect of Serenoa repens, Lycopene, and Selenium on Proinflammatory Phenotype Activation: An In Vitro And In Vivo Comparison Study, Urology, vol.77, issue.1, pp.248-249, 2011.
DOI : 10.1016/j.urology.2010.07.514

R. Vela-navarrete, J. V. Garcia-cardoso, A. Barat, F. Manzarbeitia, and A. Lopez-farre, BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay, European Urology, vol.44, issue.5, pp.549-555, 2003.
DOI : 10.1016/S0302-2838(03)00368-3

A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the National Academy of Sciences of the United States of America, pp.15545-15550, 2005.

Y. Bostanci, A. Kazzazi, S. Momtahen, J. Laze, and B. Djavan, Correlation between benign prostatic hyperplasia and inflammation, Current Opinion in Urology, vol.23, issue.1, pp.5-10, 2013.
DOI : 10.1097/MOU.0b013e32835abd4a

A. Cardi, G. Salvatori, and A. Sciarra, Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) European urology, pp.72-78, 2005.

S. K. Addla, A. B. Adeyoju, D. Neilson, and P. O-'reilly, Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study, European Urology, vol.49, issue.4, pp.720-725, 2006.
DOI : 10.1016/j.eururo.2005.11.026

R. Vela-navarrete, J. Garcia-cardoso, A. Barat, F. Manzarbeitia, and A. Lopez-farre, Effects of the lipido-sterolic extract of Serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate The Prostate, European urology, vol.62, issue.56, pp.171-182, 2002.

L. Liu, Q. Li, P. Han, X. Li, H. Zeng et al., Evaluation of Interleukin-8 in Expressed Prostatic Secretion as a Reliable Biomarker of Inflammation in Benign Prostatic Hyperplasia, Urology, vol.74, issue.2, pp.340-344, 2009.
DOI : 10.1016/j.urology.2009.02.064

J. M. Schenk, A. R. Kristal, M. L. Neuhouser, C. M. Tangen, E. White et al., Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial, American Journal of Epidemiology, vol.171, issue.5, pp.571-582, 2010.
DOI : 10.1093/aje/kwp406

G. Penna, N. Mondaini, S. Amuchastegui, S. Degli-innocenti, M. Carini et al., Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia, European Urology, vol.51, issue.2, pp.524-533, 2007.
DOI : 10.1016/j.eururo.2006.07.016

E. Ryschich, G. Huszty, H. P. Knaebel, M. Hartel, M. W. Buchler et al., Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas, European Journal of Cancer, vol.40, issue.9, pp.1418-1422, 2004.
DOI : 10.1016/j.ejca.2004.01.036

O. Donnell, K. A. Yu, D. Zeller, K. I. Kim, J. W. Racke et al., Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Molecular and cellular biology, pp.2373-2386, 2006.

S. Wada, T. Noguchi, S. Takeno, and K. Kawahara, PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma, Annals of Surgical Oncology, vol.94, issue.7, pp.961-966, 2006.
DOI : 10.1245/ASO.2006.08.006

J. Y. Song, J. K. Lee, N. W. Lee, H. H. Jung, S. H. Kim et al., , and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer, International Journal of Gynecological Cancer, vol.18, issue.5, pp.1051-1059, 2008.
DOI : 10.1111/j.1525-1438.2007.01164.x

T. Schlomm, O. J. Hellwinkel, A. Buness, M. Ruschhaupt, A. M. Lubke et al., Molecular Cancer Phenotype in Normal Prostate Tissue, European Urology, vol.55, issue.4, pp.885-890, 2009.
DOI : 10.1016/j.eururo.2008.04.105

A. Essaghir, J. B. Demoulin, L. Tacchini, E. Gammella, C. De-ponti et al., A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers Role of HIF-1 and NFkappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. The Journal of biological chemistry, Immunological reviews 2012, pp.20674-20686, 2008.

B. Paule, S. Terry, L. Kheuang, P. Soyeux, F. Vacherot et al., The NF-kappaB/IL- 6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World journal of urology, pp.477-489, 2007.

C. A. Blindauer and O. I. Leszczyszyn, Metallothioneins: unparalleled diversity in structures and functions for metal ion homeostasis and more, Natural Product Reports, vol.423, issue.Supplement 1, pp.720-741, 2010.
DOI : 10.1039/b906685n

W. Swindell, Metallothionein and the biology of aging Ageing research reviews, pp.132-145, 2011.

M. Paubert-braquet, F. O. Richardson, N. Servent-saez, W. C. Gordon, M. C. Monge et al., Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat Pharmacological research : the official journal of the Italian Pharmacological Society A signaling network in phenylephrine-induced benign prostatic hyperplasia, Endocrinology, vol.34, issue.150, pp.171-179, 1996.

F. G. Rick, A. V. Schally, N. L. Block, M. Nadji, K. Szepeshazi et al., Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia, Proceedings of the National Academy of Sciences of the United States of America, pp.3755-3760, 2011.
DOI : 10.1073/pnas.1018086108

P. Castro, C. Xia, L. Gomez, D. J. Lamb, and M. Ittmann, Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. The Prostate, pp.153-159, 2004.

A. Reiner, D. Yekutieli, and Y. Benjamini, Identifying differentially expressed genes using false discovery rate controlling procedures, Bioinformatics, vol.19, issue.3, pp.368-375, 2003.
DOI : 10.1093/bioinformatics/btf877

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=